SALT LAKE CITY and TORONTO and MONTRÉAL, May 08, 2023 (GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, today ...
After a year defined by pipeline cuts, the departure of its CEO and layoffs, Exscientia will merge into Recursion, creating one company that has 10 clinical readouts to look forward to over the next ...
Recursion Pharmaceuticals has agreed to acquire the Oxford, U.K.-based artificial intelligence (AI) drug pioneer Exscientia, the companies said today, in a deal that consolidates two leaders in ...
Scientists in Spain have implemented recursive least squares (RLS) algorithms for anomaly detection in PV systems and have found they can provide “more realistic and meaningful assessment” than ...
Recursion is using AI and machine learning to accelerate drug research and development. The stock has been under pressure amid an uncertain near-term financial outlook. Several clinical updates from ...
Digitally enabled drug discovery for oncology with potential to accelerate the delivery of new cancer therapies to patients Drug discovery research collaboration may initiate up to seven oncology ...
SALT LAKE CITY, Feb. 28, 2025 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX) a leading clinical stage TechBio company decoding biology to radically improve lives, today reported business updates and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results